Human CD79B Antibody
R&D Systems, part of Bio-Techne | Catalog # AF6620
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
Chinese hamster cell line CHO-derived recombinant human CD79B
Ala29-Asp159
Accession # P40259
Ala29-Asp159
Accession # P40259
Specificity
Detects human CD79B in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse CD79B is observed.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human CD79B Antibody
Detection of Human CD79B by Western Blot.
Western blot shows lysates of Nalm-6 human Pre-B acute lymphocytic leukemia cell line. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human CD79B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6620) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for CD79B at approximately 40kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
Detection of CD79B in Human peripheral blood lymphocytes by Flow Cytometry.
Human peripheral blood lymphocytes were stained with Sheep Anti-Human CD79B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6620) followed by NorthernLights™ 637-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # NL011) and Mouse Anti-Human CD19 PE-conjugated Monoclonal Antibody (Catalog # FAB4867P). Quadrant markers were set based on control antibody staining (Catalog # 5-001-A).Applications for Human CD79B Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
2.5 µg/106 cells
Sample: Human peripheral blood lymphocytes
Sample: Human peripheral blood lymphocytes
Western Blot
0.5 µg/mL
Sample: Nalm‑6 human Pre-B acute lymphocytic leukemia cell line
Sample: Nalm‑6 human Pre-B acute lymphocytic leukemia cell line
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Sterile PBS to a final concentration of 0.2 mg/mL. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD79B
CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is expressed on B cells, and forms a covalent heterodimer with 44-49 kDa CD79A. This complex interacts noncovalently with membrane Ig, forming the B cell antigen receptor. Within this complex, membrane Ig detects antigen while CD79A:B initiates signaling. Mature human CD79B is a 201 amino acid (aa) type I tranamembrane glycoprotein (aa 29‑229). It contains an extracellular region with one V-type Ig-like domain (aa 38-138) and an ITAM-containing cytoplasmic domain (aa 181-229). There is an alternative splice form that shows a deletion of aa 41-144 and appears after B cell activation. Human CD79A and B share only 26% aa identity. Over aa 29-159, human CD79B shares 54% aa identity with mouse CD79B.
Alternate Names
B29, CD79B, IGB
Gene Symbol
CD79B
UniProt
Additional CD79B Products
Product Documents for Human CD79B Antibody
Product Specific Notices for Human CD79B Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...